Repetitive mild traumatic brain injury (r-mTBI) is a risk factor for Alzheimer disease (AD). The precise nature of how r-mTBI leads to, or precipitates, AD pathogenesis remains unclear. In this study, we explore subchronic effects of chronic r-mTBI (12-impacts) administered over 1-month in aged-PS1/APP mice and littermate controls. We investigate specific mechanisms that may elucidate the molecular link between AD and r-mTBI, focusing primarily on amyloid and tau pathology, amyloid processing, glial activation states, and associated clearance mechanisms. Herein, we demonstrate r-mTBI in aged PS1/APP mice does not augment, glial activation, amyloid burden, or tau pathology (with exception of pS202-positive Tau) 1 month after exposure to the last-injury. However, we observed a decrease in brain soluble Ab42 levels without any appreciable change in peripheral soluble Ab42 levels. This was accompanied by an increase in brain insoluble to soluble Ab42 ratio in injured PS1/APP mice compared with sham injury. A parallel reduction in phagocytic receptor, triggering receptor expressed on myeloid cells 2, was also observed. This study demonstrates very subtle subchronic effects of r-mTBI on a preexisting amyloid pathology background, which may be on a continuum toward a slow and worsening neurodegenerative outcome compared with sham injury, and therefore, have many implications, especially in the elderly population exposed to TBI.
INTRODUCTION
Numerous reports have demonstrated that exposure to repetitive mild traumatic brain injury (r-mTBI) is a risk factor for the development of later-life dementias, such as Alzheimer disease (AD) and chronic traumatic encephalopathy (1) (2) (3) (4) (5) (6) (7) (8) .
In sports-related concussions, such as American Football, retired professional players exposed to recurrent concussions have been strongly linked to a high risk for late-life cognitive impairment (9) . Some of the first clues linking TBI and AD originated from studies demonstrating increased amyloid beta protein levels in autopsy derived material from up to 30% patients dying acutely following TBI, and in pericontussional tissue surgically excised from survivors of TBI (10) (11) (12) (13) . This has also been confirmed in neuroimaging studies, where the PET ligand Pittsburgh B (PiB) was shown to concentrate in the gray matter and striata of TBI survivors (14) .
The precise nature of how r-mTBI leads to or precipitates AD pathogenesis is not currently understood. Animal models could be key to deciphering these pathophysiological mechanisms, as they could facilitate insight into the poorly understood role that TBI plays in the onset/progression of AD, and also enable identification of novel therapies that can be translated from bench to bedside.
Several animal models demonstrating a hallmark amyloid pathologies of AD have been used to study repetitive TBI. Some of these studies have reported augmentation of amyloid pathology at acute to subchronic time points postTBI (15) (16) (17) (18) , whereas other reports show regression in age-related amyloid pathology, especially at chronic time points postinjury (19) (20) (21) . In human cases of repetitive mTBI, the role of amyloid pathology also remains controversial, nevertheless approximately 50% of confirmed chronic traumatic encephalopathy cases show amyloid pathology (22) . In addition, the relationship between amyloid and tau pathology also remains unclear in TBI (7, (22) (23) (24) .
To date, only a few preclinical studies have investigated the molecular link between repetitive mTBI and AD, with some of these studies showing impairment in underlying neuroinflammatory processes, oxidative stress and protein clearance mechanisms (25) (26) (27) . However, most of these studies have only focused on low frequency of impacts at the preamyloid pathology stage; and only a few have explored time points beyond a few days or weeks postinjury. Also, little is currently known about the effects of prolonged repetitive mTBI on aged animals with preexisting amyloid and how this may precipitate tau pathology, as this can be vital in understanding the risk for the development of AD in elderly patients exposed to TBI (e.g. in incidence of repeated falls).
In this study, we explore the subchronic effects of chronic repetitive mTBI (12 impacts) over a period of 1 month in an aged mouse model with preexisting amyloid pathology. We use the PSAPP mouse model (PS1[M146L], APP [K670N, M671L]), a very well-characterized model of AD (28) (29) (30) that exhibits progressive age-dependent development of amyloid pathology in an accelerated manner compared with other models such as the Tg2576 mice that carry 1 (Swedish) mutation alone. We also investigate specific underlying molecular mechanisms that may bridge the gap between repetitive mTBI and increased AD risk, focusing primarily on markers of tau pathogenesis, amyloid processing and catabolism, glial activation and glial mediated scavenger and phagocytic clearance. We demonstrate herein that repetitive mTBI in aged PSAPP mice does not augment amyloid burden, extent of cerebral amyloid angiopathy (CAA), glial activation or levels of tau species (with exception of pS202-positive tau), 2 months after exposure to the first injury. However, we observed a reduction in soluble Ab42 levels (without any appreciable changes in soluble plasma Ab42) in cortical brain homogenates of injured aged PSAPP mice compared with sham counterparts, and this correlated with a significant increase in insoluble to soluble Ab42 ratio. A parallel reduction in phagocytic clearance receptor, triggering receptor expressed on myeloid cells 2 (TREM-2) was observed with injury in aged PSAPP mice. This study demonstrates very subtle effects of repetitive mTBI on aged mice with preexisting amyloid pathology that may be on a continuum toward worsening neuropathological outcome.
MATERIALS AND METHODS

Animals
All experiments were performed in accordance with Office of Laboratory Animal Welfare and National Institutes of Health guidelines under a protocol approved by the Roskamp Institute Institutional Animal Care and Use Committee (IACUC -R056). The mouse model used transgenic (PSAPP) mice expressing APP KM670/671NL (Swedish), PSEN1 M146L on a C57BL/6 background (generated as previously described in [28] ). Mice were around 16 months of age at the start of this study. Animals were housed in standard cages under a 12-hour light/12-hour dark schedule at ambient temperature controlled between 22 C and 23 C under specific pathogen-free conditions. Animals were given food and water ad libitum and maintained under veterinary supervision throughout the study. There was no evidence of disease among the colony. Mice of both sexes were randomly assigned to experimental groups. For the behavioral experiments, groups consisted of wild type (WT) sham (n ¼ 6), WT TBI (n ¼ 9), PSAPP sham (n ¼ 5), and PSAPP TBI (n ¼ 6). For histopathology and immunoblotting studies, groups consisted of n ¼ 5-6/group, except for immunoblotting studies where sham PSAPP mice consisted of n ¼ 3-4 due to statistically significant outliers. All analyses were carried out blind to study group assignment.
Experimental mTBI
The experimental TBI methods were performed as previously described (31, 32) . Briefly, mice were anesthetized with 1.5 L/minute of oxygen and 3% isoflurane for 3 minutes. After shaving of the injury site, mice were transferred into a stereotaxic frame (Just For Mice Stereotaxic, Stoelting, Wood Dale, IL) mounted with an electromagnetic controlled impact device (Impact One Stereotaxic Motorized Impactor, Richmond, IL). Heads were positioned and fixed in the device, which prevented lateral movements as the impact was delivered. All mice were placed on a heating pad to maintain their body temperature at 37 C. A 5-mm blunt metal impactor tip attached to the electromagnetic motorized device was zeroed on the scalp and positioned above the midsagittal suture before each impact using the NeuroLab controller. On satisfactory positioning, the tip was retracted and the depth was adjusted to the desired level. The scalp was gently stretched by hand to restrict lateralization of the impact and to prevent the rod from delivering an inadequate trauma load at an irregular angle. Injury parameters were 5 m/second strike velocity, 1.0-mm strike depth, 200 milliseconds dwell time, and a force of 72 N. This sublethal impact does not cause direct tissue damage to the injury site, and there is no development of skull fracture or subdural hemorrhage, even after repetitive injuries. Mice in the r-mTBI group received 3 impacts every week (Monday, Wednesday, and Friday) for 1 month (12 impacts), an interinjury time of 48-72 hours. Repetitive sham control mice received anesthesia's of the same frequency (Â12) and duration ($3 minutes per session) as their r-mTBI counterparts. Animals were grouped as repetitive shams or repetitive injury. After each impact was delivered, the mice were allowed to recover on a heating pad set at 37 C to prevent hypothermia. On becoming ambulatory, mice were returned to their cages and carefully monitored for any abnormalities.
Three-Chamber Test for Social Novelty Recognition Test
Neurobehavioral tests were conducted 1 month following last injury. Social memory was quantified using a rectangular 3-chamber test that includes a middle chamber with 2 doors leading to 2 separate (left and right) chambers, each containing a steel cage enclosure. After 5 minutes of habituation in the 3-chamber compartment, each mouse (experimental subject) was placed in the middle chamber and allowed to freely explore for 5 minutes, with the right chamber empty except for an unfamiliar congener (Stranger I) held in the steel cage enclosure in the left chamber. To measure social memory (novelty recognition), a new novel stimulus mouse (Stranger II) was subsequently placed in the previously empty right chamber and preference of the experimental subject for Strangers I or II was determined by measuring the number of 
Brain Tissue Preparation and Western Blotting
One month after the last injury brain tissue was collected following transcardial perfusion by gravity drip with phosphate buffered saline (PBS). One hemisphere was extracted and parietal cortex region was dissected, flash frozen in liquid nitrogen and kept at À80 C for antibody based/biochemical analyses. The other hemisphere was postfixed in 4% paraformaldehyde for histological/immunohistochemical (IHC) analyses. For Western blotting analyses, the dissected parietal cortex from each hemisphere were homogenized in 150 ml of MPER buffer (pH 7.4) containing proteinase inhibitor cocktail, using a probe sonicator. Homogenized samples were spun in a centrifuge at 20 000 rcf for 30 minutes and tissue supernatants were collected. Supernatant fractions were denatured at 100 C by boiling in Laemmli buffer (Bio-Rad, Hercules, CA). Samples were then subsequently resolved on 4%-20% gradient polyacrylamide criterion gels (Bio-Rad) or 4%-12% gradient NuPAGE novex Bis-Tris precast polyacrylamide gels (Life Technologies, Grand Island, NY). After electrotransferring, polyvinylidene difluoride membranes were blocked in 5% milk or normal rabbit serum (for only goat primary antibodies) made in tris buffered saline, and subsequently immunoprobed for different brain-specific primary antibodies overnight (Supplementary Data Table S1 ). After a rigorous washing step, membranes were probed with horseradish peroxidase linked secondary antibodies (Supplementary Data Table S1). For primary antibodies raised in mouse host species, a 20% super blocking buffer was used in the secondary antibody solution. Immunoblots were analyzed by using a housekeeping gene, GAPDH (or total protein levels), to quantify the amount of proteins electrotransferred, and signal intensity ratios were quantified by chemiluminescence imaging with the ChemiDocTM XRS (Bio-Rad).
ELISA
Preparation of detergent soluble Ab and resolubilization of insoluble Ab with guanidine for PSAPP mice: briefly, brains were homogenized at 4 C in MPER reagent (Thermo Fisher Scientific, Rockford, IL) containing 1 mM phenylmethane sulfonyl fluoride and 1Â protease/phosphatase inhibitors cocktail (Thermo Fisher Scientific) and centrifuged at 15 000g for 30 minutes at 4 C. The supernatant containing detergent solubilized Ab was collected and denatured in 5 M guanidine isothyocianate in 50 mM Tris-HCL pH8 for 1 hour before dilution with the sample diluent provided in the enzyme-linked immunosorbent assay (ELISA) kit and assessed for soluble Ab42 levels according to the manufacturer's protocol (Thermo Fisher Scientific). The pellet containing detergent insoluble material was resuspended in 5 M guanidine isothyocianate in 50 mM Tris-HCL pH8 and left for an hour before dilution with the sample diluent provided in the ELISA kit for assessment of insoluble Ab42 levels. Soluble Ab40 levels were measured using ELISA method. Brain homogenates diluted in MPER buffer were centrifuged at 21 000 rcf for 30 minutes, and the collected supernatant fractions at 1/5 and 1/20 dilutions for WT and PSAPP mice were run on the Ab40 ELISA kits as instructed by the manufacturer's guide (Wako, Osaka, Japan). Protein concentrations were measured in the guanidine extracts using the BCA method (Life Technologies, Carlsbad, CA) and results of brain Ab40 and Ab42 levels were calculated in ng/mL per mg protein.
Immunohistochemistry/Immunofluorescence
Half brain hemispheres (left side) were embedded in 4% paraformaldehyde for 24-48 hours followed by paraffin embedding. Series of 6-mm thick sagittal sections were cut throughout the extent of the cortex and hippocampus guided by known bregma coordinates using a microtome (2030 Biocut, Reichert/Leica, Buffalo Grove, IL). Cut sections were mounted onto positively charged glass slides (Fisher, Superfrost Plus, Pittsburgh, PA).
Sections were deparaffinized in histoclear and rehydrated in a decreasing gradient of ethanol before the IHC procedure. Sections for IHC were rinsed in distilled water and subsequently incubated at room temperature in a solution of endogenous peroxidase blocking solution containing 3% hydrogen peroxide diluted in PBS for 15 minutes. For primary antibodies requiring antigen retrieval, sections were treated by microwave irradiation with citrate buffer solution (pH 6) for 8 minutes. Following antigen retrieval sections were blocked for 30 minutes to 1 hour in either (i) Dako protein serum free protein block (Dako, Carpinteria, CA), (ii) normal blocking serum to which secondary antibody was raised, or (iii) mouse immunoglobulin G blocking reagent mouse on mouse Kit (Vectors Laboratories, Burlingame, CA). Sections were stained in batches with primary antibodies made up in supersensitive wash buffer or antibody diluent background-reducing agent. Primary antibodies used can be found in Supplementary Data Table S1 . For immunofluorescence (IF) staining, a cocktail of primary antibodies was prepared in supersensitive buffer. After overnight incubation, sections were rinsed with PBS and transferred to a solution containing the appropriate secondary antibody (Millipore Billerica, MA; Vectastain Elite ABC Kit, Vector Laboratories) for 30 minutes to 1 hour depending on the specific requirement of the antibody protocol. For antibodies raised in a mouse host, secondary antibodies were diluted in 20% superblock blocking buffer (Pierce, ThermoFisher Scientific, Rockford, IL). For IF staining, secondary antibodies were raised from the same host and were mixed as a cocktail. After rinsing in water, sections were incubated with avidin-biotin horseradish peroxidase (Vectastain Elite ABC kit; Vector Laboratories) solution for 30 minutes.
For IHC staining immunoreactivity was visualized with 3,3-diaminobenzidine (DAB). Development with the chromogen was timed and applied as a constant across batches to limit technical variability before progressing to quantitative image analysis. The reaction was terminated by rinsing sections in copious amounts of distilled water. Mounted sections were progressed through a graded series of alcohols (dehydrated), cleared in xylene, and coverslipped with permanent mounting medium. The IHC procedure was previously validated for most antibodies used by including negative control sections, whereby the primary mouse monoclonal antibodies were omitted and replaced with either blocking agent or biotinylated secondary antibodies alone to eliminate issues surrounding nonspecific immunoreactivity or detection of mouse immunoglobulin reacting with antimouse secondary in the tissue sample. Immunoreacted sections were viewed using a motorized Olympus (BX63) upright microscope, and photographs were taken using the high-resolution DP72 color digital camera.
Histology
A series of sections were deparaffinized and processed for histological stains. The Bielschowsky silver impregnation method was performed according to the manufacturer's guidelines to reveal amyloid plaques (Hitobiotec, Kingsport, TN). Congo red staining for amyloid plaque was performed using manufacturer's instructions (Sigma, St Louis, MO). To detect microhemorrhages in the brain tissue a Prussian blue staining was also performed according to the manufacturer's guidelines (ENG Scientific, Inc., Clifton, NJ). Sections were subsequently processed through a descending gradient of alcohol, xylene, and coverslipped with Permount mounting medium. Thioflavine-S staining to visualize amyloid plaques was performed by incubating sections after IF staining in 0.1% Thioflavine-S solution (Sigma) dissolved in 70% ethanol.
Image Analysis
Immunoreactivity for microglia and astrocyte cellular markers, APP and 4G8 were measured by quantitative image analysis (optical segmentation). Rigorous staining protocols were applied to ensure consistency of immunostaining and accuracy of image analysis. Analysis was performed blind to experimental conditions using coded slides to avoid bias in evaluation. Multiple regions of interest were analyzed in standardized fashion for each antibody. First, a survey of immunostained tissue sections was performed independently to verify specific immunoreactivity that was subsequently progressed to quantitative image analysis. Briefly, nonoverlapping red, green, blue (RGB) images were digitally captured randomly within the defined areas from each section (comprising an average of 3 sections per animal for each marker) and 10-15 microscopic fields (Â40 or Â60 magnification) were analyzed per region per animal. Immunoreacted profiles that were optically segmented were analyzed using CellSens morphometric image analysis software (Olympus, Center Valley, PA). A semiautomated RGB histogram-based protocol (specified in the image analysis program) was used to determine the optimal segmentation (threshold setting) for immunoreactivity for each antibody. Immunoreactive profiles discriminated in this manner were used to determine the specific immunoreactive percentage area. Data were separately plotted as the mean percentage area of immunoreactivity per field (denoted "% area") 6 SEM for each region and grouping. Amyloid plaque density and CAA-positive vessels were obtained on the same images of 4G8 captured above. Clearly discernable compact neuritic plaques and vessels with positive 4G8 staining were counted on serial sections and images captured and expressed as density estimates per area square.
Statistical Analysis
The relationships between mTBI and sham animals for Western blotting, IHC and ELISA were assessed by using either a parametric One-way ANOVA or nonparametric Kruskal-Wallis test with a predefined criterion of p < 0.05 to assess group differences. For tau immunoblots, a t-test was used for analyses between sham versus injured PSAPP or WT mice. Neurobehavioral data was analyzed using nonparametric Man-Whitney U test for comparison between time spent in Stranger I versus Stranger II chambers. Data were analyzed by the Kolmogorov-Smirnov test to evaluate if data sets fitted the normal Gaussian distribution. All analyses were performed with SPSS 21.0 (IBM Corp., Armonk, NY) and Graphpad Prism (La Jolla, CA) statistical software.
RESULTS
Neurobehavioral Outcome in Aged Transgenic AD Mice After Chronic Repetitive mTBI
Aged WT and PSAPP mice performed poorly in the social novelty recognition test used to evaluate social memory (Supplementary Data Fig. S1 ). Injured aged WT mice also showed an impairment in social memory; however, this was not significantly worse than aged WT or PSAPP sham mice (Supplementary Data Fig. S1 ). Intriguingly, chronic repetitive mTBI did not augment impairment in social memory in aged PSAPP mice, and injured animals performed better than sham mice with Stranger II, spending 30% more time than in Stranger I chamber (Supplementary Data Fig. S1 ).
Tau Modification in Aged Transgenic AD Mice After Chronic Repetitive mTBI
We examined total tau (DA9), phospho-tau (RZ3-Thr231, PHF1-S396/404, CP13-s202), tau conformer species (MC1), tau oligomers (TOC1), N terminal phosphatase activation domain of tau (TNT-1) and caspase cleaved tau (tau C3) in the parietal cortex of WT and PSAPP mice by immunoblotting. No injury-dependent effect was observed for most tau antibodies in both WT and PSAPP mice compared with sham counterparts ( Fig. 1A-H; Supplementary Data Fig. S2 ). A significant effect was observed for CP13 levels in injured compared with sham PSAPP mice (p ¼ 0.03) (Fig. 1D) . Immunohistochemistry of CP13, PHF1 ( Fig. 2A-H [see inset A'B' and E'F']), RZ3, and TauC3 (Fig. 3AA '-DD') in PSAPP mice showed a widespread periamyloid plaque staining of seemingly dystrophic neurites. Corresponding with the immunoblotting data no notable changes were observed in the immunoreactivity levels of most of these tau antibodies between sham and injured PSAPP mice. Only CP13 immunoreactivity levels appeared to be mildly increased in the cortex and CA3 pyramidal neurons of some injured PSAPP compared with sham animals ( Fig. 2A, C vs B, D) .
Amyloid Pathology in Aged Transgenic AD Mice After Chronic Repetitive mTBI
We examined APP-positive white matter pathology, amyloid plaque burden, amyloid plaque and CAA-positive FIGURE 1. Tau protein changes in parietal cortex of aged PSAPP and WT mice 1 month after repetitive mTBI. We analyzed 8 different tau-specific antibodies (normalized to GAPDH): total tau (A: DA9), phospho-tau (B: RZ3-Thr231, C: PHF1-S396/404, and D: CP13-s202), tau conformer species (MC1), tau oligomers (TOC1), N terminal phosphatase activation domain of tau (TNT-1) and caspase cleaved tau (tau C3) in the parietal cortex (located beneath the impact site). We did not observe any statistically significant changes in 7 of the different tau species analyzed in the injured PSAPP or WT animals compared with their sham counterparts (A-H). A significant effect (p ¼ 0.03) was noticeable in CP13 levels between sham and injured PSAPP animals (D). Data were analyzed using a t-test. Graphs are presented as a percentage of respective shams as they were conducted on separate immunoblotting membranes. Abbreviation: WT, wild-type; rmTBI, repetitive mild traumatic brain injury. Asterisk denotes *p < 0.05. vessel density, soluble Ab40 levels and soluble Ab42 levels in the brain and plasma, and insoluble Ab42 in the brain. There was a notable significant increase in APP immunoreactivity in PSAPP compared with WT mice (Fig. 4A) . However, APP immunoreactivity in the white matter was not statistically different between sham and injured animals in both aged WT and PSAPP mice (Figs. 4A and 5A, B). No change was observed in APP immunoreactivity in the cortex of sham versus injured aged PSAPP mice (Fig. 5C, D) . Both amyloid plaque burden (Fig. 4B ), amyloid counts ( Fig. 4C ) and CAA-positive vessels (Fig. 4D) were unchanged in all brain regions examined in sham versus injured aged PSAPP mice. This is supported by micrographs from 4G8 (Fig. 6A, B ) and Bielschowsky staining (Fig. 6C-F) showing no overt or significant difference in the representative images presented. A trend toward increase in soluble Ab40 levels in the parietal cortex was observed in injured PSAPP mice compared with shams, however, this did not reach statistical significance (Fig. 4E) . No change was observed in soluble Ab40 levels between sham and injured aged WT mice (Fig. 4E) . Soluble Ab42 was significantly reduced in the parietal cortex of injured compared with sham PSAPP mice, and a trend toward reduction was also present in the hippocampus, however this did not reach statistical significance (Fig. 4F) . Insoluble levels of Ab42 were both significantly unchanged in the parietal cortex and hippocampus between sham and injured PSAPP mice (Fig. 4G) , no change was also observed in soluble Ab42 levels in the plasma (Fig. 4H) . We expressed the levels of soluble Ab42 to Ab40 ratio and insoluble to soluble Ab42 ratio in the brain. Our observations show a marginally significant reduction (75%) in soluble Ab42 to Ab40 ratio in the parietal cortex of injured compared with sham PSAPP mice (Fig. 4I) . A significant increase in insoluble to soluble Ab42 levels was demonstrated in the parietal cortex of injured compared with sham animals (Fig. 4J) , no statistically significant effect was seen in the hippocampus (Fig. 4J ).
Astrocyte and Microglia Cellular Markers in Aged Transgenic AD Mice After Chronic Repetitive mTBI
Astrocyte activation was examined using glial fibrillary acidic protein (GFAP) immunoreactivity. PSAPP mice showed a significant increase in percentage area of GFAP immunoreactivity compared with WT mice in the cortex, hippocampus and corpus callosum (Figs. 7A and 8A , B, E, F, I, J vs C, D, G, H, K, L). GFAP-positive astrocytes were found around amyloid plaques in the brain parenchyma (Fig. 8C inset) and blood vessels (Fig. 8K inset) 
. Amyloid pathology in the brain of aged PSAPP mice 1 month after repetitive mTBI. We examined APP immunoreactivity in the corpus callosum (A), amyloid plaque burden (B), and density (C), CAA-positive vessels (D), soluble Ab40 (E), and soluble Ab42 (F), insoluble Ab42 (G), and plasma Ab42 levels (H), soluble Ab42 to Ab40 ratio (I), and insoluble to soluble Ab42 levels (J). Transgenic PSAPP mice showed a significantly higher level of APP immunoreactivity in the corpus callosum compared with WT mice; however, there were no injury-specific effects on APP immunoreactivity in either WT or PSAPP mice (A). Amyloid plaque burden (B) and counts (C) were not significantly different between injured and sham PSAPP mice in any of the regions analyzed. CAA-positive vessel density was also unchanged between sham and injured PSAPP mice. We did observe a 2.9-fold increase in soluble Ab40 levels in the parietal cortical homogenates in injured PSAPP (1.03 6 0.38 pmol/L) compared with sham animals (0.549 6 0.15 pmol/L), however, this did not reach statistical significance; no changes were found in WT sham (0.258 6 0.012 pmol/L) versus WT injury (0.238 6 0.03 pmol/L) mice (E). There was a significant decrease in soluble Ab42 levels in the parietal cortex of injured compared with sham mice (F), a 54% reduction was also observed in the hippocampus; however, this did not reach statistical significance (F). Insoluble Ab42 levels remained unchanged in the hippocampus of PSAPP sham and injured mice, a 1.6-fold increase was observed in the parietal cortex; however, this did not reach statistical significance (G). Plasma Ab42 levels were unchanged between both sham and injured PSAPP mice (H). Ratio of soluble Ab42 to Ab40 and insoluble to soluble Ab42 in PSAPP mice are expressed in panels (I, J), respectively. A 75% reduction in soluble Ab42 to Ab40 ratio was observed in the parietal cortex of injured compared with sham animals (I). A significant 64% reduction was observed in the ratio of insoluble to soluble Ab42 in the parietal cortex, no significant change was observed in the hippocampus (J). Panel (E) is presented as a percentage of respective sham animals as data from WT and PSAPP mice were
K, O vs D, H, L, P; and 11A, E, I, M vs B, F, J, N; C, G, K, O vs D, H, L, P).
Prussian blue staining was conducted after CD45 staining to demonstrate evidence of microhemorrhages or iron in brain tissue after injury. No evidence of Prussian blue reactivity or hemosiderin laden macrophages were observed in the brain tissue examined (data not shown).
Amyloid Processing and Clearance Markers in Aged Transgenic AD Mice After Chronic Repetitive mTBI
We examined by immunoblotting the expression levels of markers of amyloid processing (BACE1), enzymatic degradation of amyloid (insulin-degrading enzyme [IDE], neprilyisn), scavenger, and phagocytic receptors (SRA1, MARCO, LOX-1, TREM-2). BACE1 levels were increased in aged PSAPP mice compared with WT sham mice; however, no injury dependent effects were observed between aged WT and PSAPP mice (Fig. 12A, H) . IDE and neprilysin levels were not significantly changed between aged PSAPP and WT mice, no injury effects was observed in both aged WT and PSAPP mice (Fig. 12B, C, H) . Scavenger receptors SR-A1 and MARCO levels were consistently unchanged in both genotypes and no injury effect was observed both aged WT and PSAPP mice (Fig. 12D, E, H) . LOX-1 expression was unchanged between aged PSAPP and WT sham mice, an injury-dependent effect was significantly observed in aged WT mice; however, this injury effect was not present in aged PSAPP mice (Fig. 12F, H) . Phagocytic receptor TREM2 levels were significantly increased by 4-fold in aged PSAPP mice compared with WT mice, a significant reduction (50%) in TREM2 levels were observed in injured aged PSAPP mice compared with their sham counterparts, however this effect was not seen in WT mice (Fig. 12G, H) .
DISCUSSION
For over the last 2 decades researchers have investigated the idea that blows to the head could increase the levels of intracerebral expression of Ab (10, 11, 33, 34) . Neuropathological studies have confirmed rapid and early appearances of diffuse amyloid plaque pathology in young adolescents after injury (11, 13) . However, 15 years ago, Nakagawa and colleagues reported that aged (24-month-old) PDAPP mice bearing preexisting amyloid pathology resulted in the regression of amyloid burden 4 months postinjury (21) . To date, the specific role that TBI plays in altering the course and progression of preexisting AD remains debatable. Here we attempt to address this question by expanding on the neuropathological observations of Nakagawa et al (21) . We use an aged PSAPP mouse model of repetitive mTBI with preexisting amyloid pathology. Contrary to the findings by Nakagawa et al. (21), we observed no change in glial activation, amyloid burden, including levels of most tau species (except pS202-positive tau), at 1-month postinjury. However, we show a significant reduction in soluble Ab42 levels in parallel with an increase in insoluble to soluble Ab42 ratio. This was also accompanied by the downregulation in phagocytic receptor TREM2.
Amyloid Pathology After Repetitive mTBI
Biochemical observation from previous studies utilizing 5-to 7-month-old amyloid bearing transgenic animal models have demonstrated an increase in insoluble Ab levels from 7 days (35, 36) to 2 months (27) postinjury. This trend toward an increase in insoluble Ab levels could be accounted for by aggregation of Ab42 species, as the soluble forms of Ab42 are prone to oligomerization, and are predominantly expressed in amyloid plaques. The reduction we observed in soluble brain Ab42 levels in correlation with a lack of persistent change in APP levels or their processing enzyme BACE1 therefore suggests that previously available pools are undergoing oligomerization into insoluble Ab42 aggregated material in the brain. This is supported by the higher insoluble to soluble brain Ab42 ratio that we observed in parallel with our data showing no appreciable change in soluble plasma Ab42 levels. Additionally, reductions in soluble Ab42 could also explain the trend toward improvement in social memory because soluble Ab42 is known to be neurotoxic and can impair synaptic plasticity/function and learning and memory processing. In accordance with our biochemistry results, clinical studies have shown a decrease in soluble Ab levels in the cerebrospinal fluid (CSF) (37) and interstitial fluid (ISF) in correlation with worsening outcome (38) , and this has likewise been confirmed in a cortical contusion injury model in WT mice and 3 different lines of transgenic AD mice (39) . However, it is also worth mentioning that other studies have conversely reported eleva- tions in soluble Ab levels following TBI. For example, reports of an immediate increase in soluble Ab42 levels in the CSF (33, 40, 41) and ISF have been shown in patients following severe TBI and diffuse axonal injury (42), respectively. Moreover, in young-adult animal models that develop AD pathology, elevations in brain Ab levels in ipsilateral impact sites have been reported as rapid as 24 hours and in some cases 6 weeks postTBI (17, (43) (44) (45) . Similar trends in young-adult nontransgenic AD rodents and porcine swine models have also been confirmed, showing a surge in brain Ab accumulation from few hours to days following injury (15, (45) (46) (47) (48) (49) , and in 1 case up to 6 months (45) .
There are several possible explanations behind some of the lack of coherent findings. It is possible that in animal mod-FIGURE 7. Effect of repetitive mTBI in aged WT and PSAPP mice on astroglial and microglial cellular markers. We analyzed astroglial (GFAP) and microglial (IBA1, CD45, MHCII, CD68, F4/80) cellular markers in different brain regions 1 month after repetitive mTBI in aged WT and PSAPP mice. There was a significant increase in the expression of these markers in all brain regions of sham PSAPP mice compared with sham WT mice (A-E). No significant effect was observed in the percentage area of GFAP (A), IBA1 (B), CD45 (C), MHCII (D), and CD68 (E) immunoreactivity, in either WT or PSAPP injured mice compared with their counterparts. F4/80 immunoreactivity was mainly detected in PSAPP mice, however also no effect was observed between sham and injured PSAPP mice (F). Data were analyzed using nonparametric Kruskal-Wallis test (A-E) or Mann-Whitney U test (F). Data represent mean 6 SEM. Mean sample size is n ¼ 5. Asterisk denotes ***p < 0.001. Abbreviation: ir, immunoreactivity; APP, amyloid precursor protein; CC, corpus callosum; CTX, cortex; HP, hippocampus; THL, thalamus; WT, wild-type; rmTBI, repetitive mildtraumatic brain injury.
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els or clinical studies where there is a surge in Ab levels, widespread increase in production of APP and/or their enzymatic cleavage may be ongoing. Accumulation of APP along the length of axons or axonal bulbs is a common feature of multifocal axonal pathology. Large reservoirs of APP in the injured axons have been suggested as a source of amyloid plaques following cleavage by BACE1 (or secretase enzymes) to Ab (24) . Upregulation of BACE1 has been shown in humans and several animal models of TBI, including those mentioned above which show a surge in Ab levels after injury (45, (50) (51) (52) . Conversely, in those studies showing a reduction in Ab42 levels, it is possible that the consequences of the experimental TBI may have minimal effects on widespread levels of APP (i.e. focal rather than diffuse), their processing and/or biogenesis of Ab, and this can result in the oligomerization of available pools of soluble Ab42 into insoluble species. Additional factors that may alter Ab dynamics postinjury include but are not limited to: mutant-specific postinjury effects, choice of transgenic mouse model, type of experimental TBI, severity of injuries, chronicity of impacts (single vs repetitive), sensitivity of detection methods and choice of samples (brain region, type of fluid) examined. Thus, it appears that TBI can augment the oligomerization of Ab42 species, albeit at a different pace, ultimately resulting in a gradual sink of aggregated material that has the potential to mature overtime into denser, neuritic plaques typical of advanced AD. In our advanced aged PSAPP model, we speculate that the process of oligomeriza-FIGURE 8. GFAP immunoreactivity in aged WT and PSAPP mice 1 month after repetitive mTBI. Micrographs taken from the cortex (A-D), the corpus callosum (E-H), and the CA3 hippocampus region (I-L). Astrocytes in the PSAPP mice (C, D, G, H, K, L) showed a higher immunoreactivity for GFAP compared with WT mice (A, B, E, F, I, J) in all brain regions examined. Astrocytes from PSAPP mice had thicker processes, larger cell soma, and were seen to surround the vicinity of DAPI/thioflavine S-positive amyloid positive plaques (C inset; G, H) and CAA (K inset). Cortex of WT mice was almost devoid of GFAP-positive astrocytes (A, B). No injury dependent effects were observed in both WT and PSAPP genotypes, GFAP immunoreactivity and astrocyte phenotypes appeared similar to their sham counterparts (A, E, I vs B, F, J and C, G, K vs D, H, L). Abbreviations: Thio-s, thioflavine S; BV, blood vessel.
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Pathobiology of Head Injury in Aged PS1/APP Mice tion and augmentation of amyloidosis postinjury compared with age-matched uninjured counterparts occurs at a slower pace compared with younger animals (with pre/perionset pathology), considering that these aged mice have lower comparative levels of available soluble Ab42 levels and fullblown amyloid pathology. We anticipate that examination of more chronic extended time points in our advanced aged model may thus have revealed a continuum toward an increase in amyloid burden.
Enzyme-Mediated Catabolism of Amyloid Proteins After r-mTBI
Given the changes we observed in soluble and insoluble Ab protein levels, we sought to examine markers related to the catabolism of amyloid beta protein in our model. Neprilysin is a metallo-endopeptidase and has emerged as a significant degrading enzyme in vivo capable of degrading monomeric and potentially oligomeric forms of Ab extracellularly (53) (54) (55) . Neprilysin knockout mice accumulate Ab40 and Ab42 in high levels, and sporadic AD patients show 50% reduction in neprilysin mRNA levels in areas with plaque pathology (56, 57) . Intriguingly, a relationship between a polymorphism in neprilysin and acute Ab plaque pathology following TBI has been described (58) , and this has been postulated as one of the mechanisms contributing toward the generation of plaques postinjury. Our analysis failed to show any significant effect on neprilysin levels following injury. Further investigations of an intracellular Ab catabolic enzyme, IDE, also showed no significant change between sham and injured mice. Thus, it appears that mTBI has minimal long-term effects on these enzymes and their clearance of amyloid-at least in our animal model. However, these data should be interpreted with caution because alterations in the activity of enzymes without any appreciable increase in their levels can influence enzyme kinetics and reaction.
Tau-Specific Changes After Repetitive mTBI in a Transgenic AD Model
Increase tau levels in the CSF and plasma has been consistently reported in living patients exposed to single or repetitive blows to the head (59) (60) (61) (62) (63) . A neurodegenerative tauopathy termed chronic traumatic encephalopathy, which evolves following repetitive blows to the head, has been confirmed in the brains of professional athletes exposed to recurrent concussions (22, (64) (65) (66) . In this study, we did not observe any significant changes in most of the tau species that we examined in the brain, except a very mild increase in Pathobiology of Head Injury in Aged PS1/APP Mice pS202-positive tau. The involvement of tau following experimental TBI remains to be a controversial issue (27) , with some studies showing an increase in intracerebral tau levels after TBI in WT and variety of transgenic mice (35, 36, (67) (68) (69) (70) (71) , whereas others do not (32, (72) (73) (74) . Consistent with our study, in a similar TBI model and hit paradigm that investigated tau pathology in triple transgenic mice expressing agerelated tau and amyloid pathology, the authors failed to show significant changes in any of the tau species analyzed after TBI at chronic time points even up to 1 year after injury (74) . At first glance, these studies do not seem to support a role for amyloid in seeding tau pathology in the context of TBI. However, it is noteworthy to mention that in our mouse model, which expresses murine tau, the biological conditions do not seem to favor a path toward tau pathology in vivo. Moreover, tau seeding and aggregation is a slow process that may require many months or years before it is evident. Nonetheless, these data are consistent with some of our studies in young WT mice that have murine tau background, and do not show any TBI dependent tauopathy at 24 hours, 6, 12, and 24 months' postexposure (31, 32) . Our previous studies seem to suggest that chronicity of impacts and presence of human tau isoforms along with underlying age-related tau pathology may be the necessary factors required to generate TBI dependent tau pathology in vivo (67, 71, 75) . It is worth mentioning that the impact of the slight increase in pS202-positive tau species is unknown and further time points will be needed to fully explore whether this change may be on a continuum toward worsening and persistent tau pathogenesis.
Glial Cell Function Following TBI in a Transgenic AD Model
Glial activation has been reported as a common and persistent feature following mTBI in both humans (24) and a variety of animal models (27, 32, 74, 75) . In this study, we Effects of repetitive mTBI in aged WT and PSAPP mice on specific amyloid processing and clearance markers. We examined BACE1 for amyloid processing (A), IDE and neprilysin for enzymatic degradation of amyloid protein (B, C), scavenger receptor type I (SRA1) (D), macrophage receptor with collagenous structure (MARCO) (E) and lectin-like oxidized low-density lipoprotein receptor (LOX1) (F) for scavenger receptors, and TREM-2 (G) for phagocytic clearance mechanisms. A significant increase was observed in BACE 1 expression in sham PSAPP compared with sham WT mice, however, no injury effect was hypothesized that repetitive mTBI in aged PSAPP mice with preexisting amyloid pathology and inflammation would augment glial activation states and increase amyloid pathology. We had previously shown a dramatic increase in CD45 immunoreactivity 3 weeks postinjury in aged 18-month-old hTau mice (71) . However, contrary to our initial hypothesis, repetitive mTBI in both aged WT and PSAPP mice showed no significant changes in any of the astrocyte (GFAP) and microglia (CD68, MHCII, CD45, IBA1, and F4/80) activation markers analyzed. The presence or absence of amyloid pathology did not influence the direction of glial reactivity. These findings are intriguing considering that glial cells in aged brains are thought to be in a primed state, where they gradually lose their threshold of tolerance and can become vulnerable to subsequent stimuli (76, 77 ). It appears therefore that the aged glial cells may be more resilient to mTBI than previously anticipated. It is also worthy of note that changes at acute time points (hours to days) were not examined in this model, and our knowledge about the possibility of an early transient and robust glial cell response to injury is limited. Glial cells express scavenger and phagocytic receptors involved in clearance of cellular debris and protein aggregates. These receptors have been implicated in some neurodegenerative diseases (78); however, their role following repetitive TBI remains elusive. In our analyses we observed no significant change in scavenger receptors SRA1, CD68, or MARCO in both WT and PSAPP mice with injury. Notably we observed an increase in scavenger receptor, LOX-1 in WT mice following TBI, but this change was not observed in PSAPP mice. Repetitive mTBI significantly reduced levels of phagocytic receptor TREM2 in PSAPP mice. This study is one of the first to report changes in both LOX-1 and TREM2 after repetitive mTBI. LOX-1 is a class E scavenger receptor expressed on microglia (and also endothelia) in the brain. It appears that upregulation in their levels may be a normal response to TBI as seen in WT mice. The lack of change in LOX-1 levels seen in PSAPP mice could indicate an impairment in LOX-1 receptor-mediated clearance mechanisms, and suggests that reparative mechanisms in microglia (and endothelia) preexposed to amyloid are not adequately employed after injury. TREM2 is a phagocytic receptor thought to be expressed on microglial cells, although some have confirmed a neuronal origin (79) . They have been suggested to act as off signals for aberrant microglial activation by stimulating the M2 pathways and regulating proinflammatory genes (80) . Genetic studies have demonstrated mutations in TREM2 associated with a higher risk factor for AD (81, 82 ). An increase in TREM2 is a typical feature of AD (83, 84) , and is thought to signal an overwhelmed TREM2 dependent phagocytic machinery. This is corroborated in our study showing an increase in TREM2 in PSAPP compared with WT mice. The downregulation in their levels with TBI suggests that there is a dysfunction in the transcriptional regulation of these receptors to injury. The longterm consequence of a downregulation in this receptor could be detrimental for the clearance of amyloid protein. Notably, studies looking at TREM2-deficient mice in TBI and AD have demonstrated an increase in macrophage activation (85) and amyloid burden (86) , respectively. A recent clinical study also reported concentrations of 3.50 6 1.91 and 4.50 6 1.74 ng/ mL for CSF soluble TREM2 levels (sTREM2) in 68 former NFL players with a minimum of 12 years in organized football and 21 aged-matched controls with no history of TBI or participation in contact sports (87) . Although this data was not statistically significant between both groups, a simultaneous equation regression model did reveal that CSF sTREM2 levels in former NFL players significantly impacted on the relationship between cumulative head impact index and total-tau CSF levels (87) , thus implicating the role of microglial activation (sTREM2 levels) in the pathogenesis of long-term neurological consequences associated with repetitive head impacts.
Conclusions
In summary, we report that exposure to repetitive mTBI in aged PSAPP mice does not augment amyloid burden, CAA, glial activation, and the majority of tau species examined 1 month following last injury. We did, however, observe a significant increase in insoluble to soluble Ab42 ratio accompanied by a reduction in phagocytic clearance receptor, TREM-2 in injured PSAPP mice, suggesting a slow but progressive ongoing neurodegeneration. Our findings have many implications especially in the elderly population, given the high incidence of falls and their increased risk of developing agerelated neurodegenerative diseases. Further detailed characterizations with longitudinal chronic time points, biochemical studies of mechanism implicated in amyloid beta biogenesis, and comparison with a younger cohort of mice will be needed to confirm the role that TBI has to play in precipitating pathological aging, and whether amyloid pathology is a permanent, progressive or reversible component. This repetitive mTBI model will help lay a platform to explore these questions and help identify targets to ameliorate pathological consequences of TBI. FIGURE 12 . Continued observed in either WT or PSAPP mice (A). No significant effect was observed in IDE, neprilysin, SRA1, and MARCO in aged PSAPP sham compared with WT sham mice, and there was no effect of injury in both aged WT and PSAPP mice compared with sham counterpart (B-E). A significant increase in LOX1 was shown in injured WT mice compared with shams, however, no effect was observed between sham and injured PSAPP mice, moreover we did not observe any change between both genotypes (F). There was a significant increase in TREM-2 levels in PSAPP compared with WT sham mice. No significant increase was observed in WT sham vs injured animals; however, there was a significant reduction in injured PSAPP mice compared with sham mice (G). Representative immunoblots are in panel (H). Data were analyzed using nonparametric Kruskal-Wallis test. Data represent mean 6 SEM of each marker normalized to housekeeping marker. Asterisk denotes *p < 0.05; ***p < 0.001; ****p < 0.0001. Abbreviations: WT, wild-type; rmTBI, repetitive mild traumatic brain injury.
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